Literature DB >> 35716248

Interpreting High-Sensitive Troponins in Patients with Hypertension.

Mary C McHugh1, Deborah B Diercks2.   

Abstract

PURPOSE OF REVIEW: As the high-sensitivity cardiac troponin (hs-cTn) becomes more broadly used, physicians must understand the strengths and limitations of using the hs-cTn in the hypertensive population. RECENT
FINDINGS: The most common cause of hs-cTn elevation is cardiac myocyte injury and death; alternate mechanisms for hs-cTn elevation in the absence of cardiac myocyte death are not clearly understood. Hs-cTn elevation has been found in significant proportions of patients with asymptomatic hypertension, in patients with acute hypertensive crisis, and has even been used to predict patients who will go on to develop hypertension. While the mechanisms remain undefined, there is evidence that elevations in hs-cTn are associated with both short- and long-term morbidity and mortality. While ongoing research further defines the relationship between hypertension and hs-cTn, the emergency medicine physician must make clinical decisions today regarding the utility of this increasingly used biomarker. Given the current evidence, clinical context must be utilized including a complete clinical picture, EKGs findings, and importantly serial hs-cTn when needed to establish whether myocardial injury or myocardial infarction is occurring.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Acute hypertensive crisis; High-sensitivity troponin; Hypertension

Mesh:

Substances:

Year:  2022        PMID: 35716248     DOI: 10.1007/s11906-022-01197-2

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   4.592


  1 in total

1.  Clinical Determinants of Myocardial Injury, Detectable and Serial Troponin Levels among Patients with Hypertensive Crisis.

Authors:  Giancarlo Acosta; Ahmed Amro; Rodrigo Aguilar; Waiel Abusnina; Niharika Bhardwaj; George Augustine Koromia; Mark Studeny; Affan Irfan
Journal:  Cureus       Date:  2020-01-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.